Logo image of AKBA

AKEBIA THERAPEUTICS INC (AKBA) Stock Fundamental Analysis

NASDAQ:AKBA - Nasdaq - US00972D1054 - Common Stock - Currency: USD

1.8  -0.11 (-5.76%)

After market: 1.8 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AKBA. AKBA was compared to 572 industry peers in the Biotechnology industry. AKBA has a bad profitability rating. Also its financial health evaluation is rather negative. AKBA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AKBA has reported negative net income.
In the past year AKBA has reported a negative cash flow from operations.
In the past 5 years AKBA always reported negative net income.
AKBA had a negative operating cash flow in each of the past 5 years.
AKBA Yearly Net Income VS EBIT VS OCF VS FCFAKBA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M

1.2 Ratios

AKBA has a Return On Assets of -22.20%. This is in the better half of the industry: AKBA outperforms 75.49% of its industry peers.
Industry RankSector Rank
ROA -22.2%
ROE N/A
ROIC N/A
ROA(3y)-33.74%
ROA(5y)-39.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKBA Yearly ROA, ROE, ROICAKBA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

AKBA's Gross Margin of 84.79% is amongst the best of the industry. AKBA outperforms 88.45% of its industry peers.
In the last couple of years the Gross Margin of AKBA has declined.
The Profit Margin and Operating Margin are not available for AKBA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.02%
GM growth 5Y-3.88%
AKBA Yearly Profit, Operating, Gross MarginsAKBA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

AKBA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AKBA has more shares outstanding
Compared to 5 years ago, AKBA has more shares outstanding
The debt/assets ratio for AKBA has been reduced compared to a year ago.
AKBA Yearly Shares OutstandingAKBA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
AKBA Yearly Total Debt VS Total AssetsAKBA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

AKBA has an Altman-Z score of -9.77. This is a bad value and indicates that AKBA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.77, AKBA is not doing good in the industry: 72.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.77
ROIC/WACCN/A
WACC9.9%
AKBA Yearly LT Debt VS Equity VS FCFAKBA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

AKBA has a Current Ratio of 1.52. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.52, AKBA is not doing good in the industry: 82.24% of the companies in the same industry are doing better.
A Quick Ratio of 1.21 indicates that AKBA should not have too much problems paying its short term obligations.
The Quick ratio of AKBA (1.21) is worse than 83.84% of its industry peers.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.21
AKBA Yearly Current Assets VS Current LiabilitesAKBA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.13% over the past year.
The Revenue for AKBA has decreased by -12.21% in the past year. This is quite bad
The Revenue has been decreasing by -1.29% on average over the past years.
EPS 1Y (TTM)28.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-12.21%
Revenue growth 3Y-12.91%
Revenue growth 5Y-1.29%
Sales Q2Q%-10.98%

3.2 Future

The Earnings Per Share is expected to grow by 40.61% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 20.06% on average over the next years. This is a very strong growth
EPS Next Y-11.72%
EPS Next 2Y19.04%
EPS Next 3Y33.9%
EPS Next 5Y40.61%
Revenue Next Year-22.1%
Revenue Next 2Y-3.59%
Revenue Next 3Y8.18%
Revenue Next 5Y20.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AKBA Yearly Revenue VS EstimatesAKBA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AKBA Yearly EPS VS EstimatesAKBA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AKBA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKBA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKBA Price Earnings VS Forward Price EarningsAKBA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AKBA is valued cheaply inside the industry as 93.61% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 71.78
AKBA Per share dataAKBA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as AKBA's earnings are expected to grow with 33.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.04%
EPS Next 3Y33.9%

More info and screens

0

5. Dividend

5.1 Amount

AKBA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKEBIA THERAPEUTICS INC

NASDAQ:AKBA (2/21/2025, 8:00:44 PM)

After market: 1.8 0 (0%)

1.8

-0.11 (-5.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-12 2025-03-12/amc
Inst Owners28.67%
Inst Owner Change-97.75%
Ins Owners2.6%
Ins Owner Change8.05%
Market Cap392.72M
Analysts84.44
Price Target7.31 (306.11%)
Short Float %6.99%
Short Ratio6.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.17%
Min EPS beat(2)-54.81%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)14.14%
Min EPS beat(4)-54.81%
Max EPS beat(4)100%
EPS beat(8)5
Avg EPS beat(8)2.06%
EPS beat(12)6
Avg EPS beat(12)5.57%
EPS beat(16)6
Avg EPS beat(16)-5.83%
Revenue beat(2)0
Avg Revenue beat(2)-15.51%
Min Revenue beat(2)-17.55%
Max Revenue beat(2)-13.46%
Revenue beat(4)0
Avg Revenue beat(4)-15.55%
Min Revenue beat(4)-30.64%
Max Revenue beat(4)-0.54%
Revenue beat(8)1
Avg Revenue beat(8)-10.61%
Revenue beat(12)5
Avg Revenue beat(12)9.45%
Revenue beat(16)6
Avg Revenue beat(16)6.7%
PT rev (1m)30.3%
PT rev (3m)30.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)-26.03%
Revenue NQ rev (1m)-8.68%
Revenue NQ rev (3m)-8.68%
Revenue NY rev (1m)-1.09%
Revenue NY rev (3m)-10.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.31
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 71.78
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0.78
BVpS-0.23
TBVpS-0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.79%
FCFM N/A
ROA(3y)-33.74%
ROA(5y)-39.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.02%
GM growth 5Y-3.88%
F-Score3
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 6.93
Cap/Depr 0.08%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.52
Quick Ratio 1.21
Altman-Z -9.77
F-Score3
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)0.15%
Cap/Depr(5y)3.73%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-11.72%
EPS Next 2Y19.04%
EPS Next 3Y33.9%
EPS Next 5Y40.61%
Revenue 1Y (TTM)-12.21%
Revenue growth 3Y-12.91%
Revenue growth 5Y-1.29%
Sales Q2Q%-10.98%
Revenue Next Year-22.1%
Revenue Next 2Y-3.59%
Revenue Next 3Y8.18%
Revenue Next 5Y20.06%
EBIT growth 1Y40.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.64%
OCF growth 3YN/A
OCF growth 5YN/A